DiaMedica Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

1. DiaMedica Therapeutics will present at Oppenheimer 35th Annual Conference. 2. Conference scheduled for February 12, 2025, at 11:20 AM ET. 3. DMAC's lead candidate, DM199, targets severe ischemic diseases. 4. DM199 is a recombinant form of KLK1 protein; established in Asia. 5. Management is available for investor meetings during the conference.

Corporate Developments

70

5 mins saved

Full Article

FAQ

Why Bullish?

Presentations at major conferences can attract investor interest and visibility, similar to past events that have spiked DMAC shares temporarily.

How important is it?

The event highlights important developments in DMAC's drug pipeline and investment opportunities.

Why Short Term?

The momentum from conference participation could positively influence DMAC's stock shortly after the event.

Related Companies

DM199

DiaMedica Therapeutics to Present at the Oppenheimer 35^th Annual Healthcare Life Sciences Conference

February 10, 2025 04:15 PM Eastern Standard Time

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced today that the Company’s management will present at the Oppenheimer 35^th Annual Healthcare Life Sciences Conference on February 12^th, 2025 at 11:20am Eastern Time.

Investors and attendees that would like to schedule a meeting with DiaMedica’s management can contact their Oppenheimer representative to arrange a meeting.

About DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious ischemic diseases with a focus on acute ischemic stroke and preeclampsia. DiaMedica’s lead candidate DM199 is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in Asia for the treatment of acute ischemic stroke, preeclampsia and other vascular diseases. For more information visit the Company’s website at www.diamedica.com.

Contacts

Scott Kellen
Chief Financial Officer
Phone: (763) 496-5118
skellen@diamedica.com

For Investor Inquiries:
Mike Moyer
Managing Director, LifeSci Advisors, LLC
mmoyer@lifesciadvisors.com